The Onco Life Podcast

Blood Test Could Help Predict Breast Cancer Immunotherapy Success With Liquid Biopsy Research

1 min · 19 de may de 2026
Portada del episodio Blood Test Could Help Predict Breast Cancer Immunotherapy Success With Liquid Biopsy Research

Descripción

A new study suggests that a blood test may one day help predict which breast cancer patients are more likely to benefit from immunotherapy. This emerging liquid biopsy approach focuses on immune-related signals in the blood, especially T-cell activity, to better understand treatment response in patients with HER2-negative breast cancer. In this episode, we break down what this research means for breast cancer care and why it could become an important step toward more personalized cancer treatment strategies. You’ll learn: *  What this new liquid biopsy blood test measures and how it differs from standard ctDNA testing  *  Why T-cell activity may help predict immunotherapy success  *  Key findings from the study involving 546 blood samples from 160 breast cancer patients  *  How blood transcriptomic patterns were linked to better treatment response  *  Why immunotherapy is already important for high-risk triple-negative breast cancer (TNBC)  *  How blood-based testing is becoming more common in breast cancer treatment decisions  *  Why researchers still need larger studies and validation before routine clinical use  *  What questions remain about timing, cutoffs, and treatment changes based on test results  *  How this research could lead to less invasive and more personalized cancer care in the future  This episode explores the growing role of liquid biopsy research in breast cancer treatment and why doctors are looking for smarter ways to predict immunotherapy outcomes while reducing unnecessary side effects. Blog Link: Blood Test Could Help Predict Breast Cancer Immunotherapy Success [https://oncolifecentre.com/blood-test-could-help-predict-breast-cancer-immunotherapy-success] Send us Fan Mail [https://www.buzzsprout.com/2471969/fan_mail/new] Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE [https://oncolifecentre.com/author/dr-christina-ng-van-tze/] 📍 Visit us at oncolifecentre.com [https://oncolifecentre.com] 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Onco Life Podcast!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

215 episodios

episode Personalized Cancer Vaccine Shows Long-Term Promise for High-Risk Melanoma Patients artwork

Personalized Cancer Vaccine Shows Long-Term Promise for High-Risk Melanoma Patients

In this episode, we explore promising new research on a personalized cancer vaccine that may help reduce cancer recurrence and improve long-term survival for patients with high-risk melanoma. You’ll learn: • What a personalized cancer vaccine is and how mRNA technology is being used in cancer treatment • Key findings from the Phase 2b KEYNOTE-942 melanoma trial • How the vaccine reduced the risk of distant cancer spread by 59% and recurrence or death by 49% • Why combining a personalized vaccine with an immune checkpoint inhibitor may improve outcomes • How tumor-specific neoantigens help train the immune system to recognize cancer cells • Why melanoma is an important testing ground for personalized cancer vaccines • Potential side effects and safety considerations patients should discuss with their oncologist • Why this treatment remains investigational and what Phase 3 trials could mean for future cancer care The latest five-year data suggest that personalized cancer vaccines may become an important part of future cancer treatment. While the results are encouraging, the therapy is still being studied and is not yet approved for routine use. This episode explains what patients need to know about the benefits, risks, clinical trials, and the future of personalized cancer care. Blog Link: Personalized Cancer Vaccine Shows Long-Term Promise [https://oncolifecentre.com/personalized-cancer-vaccine-shows-long-term-promise] Send us Fan Mail [https://www.buzzsprout.com/2471969/fan_mail/new] Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE [https://oncolifecentre.com/author/dr-christina-ng-van-tze/] 📍 Visit us at oncolifecentre.com [https://oncolifecentre.com] 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

Ayer1 min
episode New Targeted Drug sac-TMT Improves Survival in Advanced Endometrial Cancer artwork

New Targeted Drug sac-TMT Improves Survival in Advanced Endometrial Cancer

A new targeted cancer drug called sac-TMT is showing promising results for patients with advanced or recurrent endometrial cancer. In a major Phase 3 clinical trial, the treatment improved both overall survival and progression-free survival compared with standard chemotherapy after previous treatments stopped working. In this episode, we break down the latest TroFuse-005 trial results, how antibody-drug conjugates work, and why this development could change future treatment options for advanced endometrial cancer. You’ll learn: *  What does advanced and recurrent endometrial cancer mean  *  Why do treatment options become limited after platinum chemotherapy, and immunotherapy fail  *  What sac-TMT is and how this antibody-drug conjugate ADC targets TROP2 cancer cells  *  How the TroFuse-005 Phase 3 trial was designed and why it matters  *  What overall survival and progression-free survival actually measure in cancer trials  *  Why improving both survival endpoints is important for patients and doctors  *  How sac-TMT differs from immunotherapy and traditional chemotherapy  *  The role of biomarkers like MSI, mismatch repair deficiency, and POLE mutations in endometrial cancer  *  What researchers still need to learn from the full trial data release  *  The possible side effects linked to sac-TMT treatment  *  What FDA review and possible approval could look like in 2027  *  How targeted therapies are changing the future of cancer care  The early trial results are encouraging, especially for patients whose cancer progressed after standard treatments. However, experts are still waiting for the complete survival data, subgroup analysis, and detailed safety findings before treatment guidelines can fully change. This episode explains the science, the trial results, and the future potential of sac-TMT in clear, easy-to-understand language. Blog Link: Targeted Drug Improves Survival in Advanced Endometrial Cancer [https://oncolifecentre.com/targeted-drug-improves-survival-in-advanced-endometrial-cancer] Send us Fan Mail [https://www.buzzsprout.com/2471969/fan_mail/new] Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE [https://oncolifecentre.com/author/dr-christina-ng-van-tze/] 📍 Visit us at oncolifecentre.com [https://oncolifecentre.com] 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

29 de may de 20261 min
episode Where to Get Uterine Cancer Treatment in Malaysia: What Patients Should Know artwork

Where to Get Uterine Cancer Treatment in Malaysia: What Patients Should Know

In this episode, we discuss where to get uterine cancer treatment in Malaysia and what patients should look for when choosing the right cancer care center. From early diagnosis to surgery, chemotherapy, and radiation therapy, this episode explains how specialist-led treatment plans can improve recovery and long-term health outcomes. You’ll learn: *  What uterine cancer is and why early diagnosis matters  *  How scans, biopsies, and tests help confirm the cancer stage  *  The main uterine cancer treatment options available in Malaysia  *  When surgery is used as part of cancer treatment  *  How radiation therapy helps destroy cancer cells after surgery  *  The role of chemotherapy in slowing or stopping cancer growth  *  Why gynecologic oncologists are important in treatment planning  *  How supportive care helps manage fatigue, discomfort, and hormonal changes  *  What to consider when choosing a cancer treatment center in Malaysia  *  Why is follow-up monitoring important after treatment ends  *  How structured cancer care improves recovery and quality of life  This episode also explains how specialist-led oncology care, supportive treatment plans, and long-term monitoring help patients manage uterine cancer more effectively. Blog Link: Where to Get Uterine Cancer Treatment in Malaysia [https://oncolifecentre.com/where-to-get-uterine-cancer-treatment-in-malaysia] Send us Fan Mail [https://www.buzzsprout.com/2471969/fan_mail/new] Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE [https://oncolifecentre.com/author/dr-christina-ng-van-tze/] 📍 Visit us at oncolifecentre.com [https://oncolifecentre.com] 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

20 de may de 202619 min
episode Biotin Supplements May Interfere With Cancer Test Results: What Patients Need to Know artwork

Biotin Supplements May Interfere With Cancer Test Results: What Patients Need to Know

Doctors are warning that high-dose biotin supplements, commonly found in hair, skin, and nail products, may interfere with important cancer lab tests. For patients undergoing cancer treatment or follow-up care, inaccurate blood test results could affect treatment decisions, hormone monitoring, and tumor marker tracking. In this episode, we explain how biotin supplements can disrupt cancer-related lab testing and what patients should discuss with their healthcare team before taking over-the-counter beauty supplements. You’ll learn: *  Why biotin supplements may interfere with cancer test results  *  How vitamin B7 affects blood tests used in cancer care  *  Which lab tests may be impacted, including tumor markers, thyroid tests, hormone levels, and troponin  *  Why false lab results can delay treatment decisions or trigger unnecessary testing  *  Why do many cancer patients take hair, skin, and nail supplements during recovery  *  What doctors recommend before scheduled bloodwork, including stopping biotin at least 72 hours beforehand  *  Why is supplement disclosure important during cancer treatment and follow-up care  *  Safer alternatives for hair regrowth, including scalp cooling and topical minoxidil  *  Questions patients should ask their oncology team before taking supplements  *  How accurate lab results support safer and more effective cancer care decisions  This episode highlights an important but often overlooked issue in cancer care: how common supplements may affect the lab tests doctors rely on to guide treatment. Blog Link: Biotin Supplements May Interfere With Cancer Test Results, Doctors Warn [https://oncolifecentre.com/biotin-supplements-may-interfere-with-cancer-test-results-doctors-warn] Send us Fan Mail [https://www.buzzsprout.com/2471969/fan_mail/new] Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE [https://oncolifecentre.com/author/dr-christina-ng-van-tze/] 📍 Visit us at oncolifecentre.com [https://oncolifecentre.com] 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

19 de may de 20261 min
episode Blood Test Could Help Predict Breast Cancer Immunotherapy Success With Liquid Biopsy Research artwork

Blood Test Could Help Predict Breast Cancer Immunotherapy Success With Liquid Biopsy Research

A new study suggests that a blood test may one day help predict which breast cancer patients are more likely to benefit from immunotherapy. This emerging liquid biopsy approach focuses on immune-related signals in the blood, especially T-cell activity, to better understand treatment response in patients with HER2-negative breast cancer. In this episode, we break down what this research means for breast cancer care and why it could become an important step toward more personalized cancer treatment strategies. You’ll learn: *  What this new liquid biopsy blood test measures and how it differs from standard ctDNA testing  *  Why T-cell activity may help predict immunotherapy success  *  Key findings from the study involving 546 blood samples from 160 breast cancer patients  *  How blood transcriptomic patterns were linked to better treatment response  *  Why immunotherapy is already important for high-risk triple-negative breast cancer (TNBC)  *  How blood-based testing is becoming more common in breast cancer treatment decisions  *  Why researchers still need larger studies and validation before routine clinical use  *  What questions remain about timing, cutoffs, and treatment changes based on test results  *  How this research could lead to less invasive and more personalized cancer care in the future  This episode explores the growing role of liquid biopsy research in breast cancer treatment and why doctors are looking for smarter ways to predict immunotherapy outcomes while reducing unnecessary side effects. Blog Link: Blood Test Could Help Predict Breast Cancer Immunotherapy Success [https://oncolifecentre.com/blood-test-could-help-predict-breast-cancer-immunotherapy-success] Send us Fan Mail [https://www.buzzsprout.com/2471969/fan_mail/new] Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE [https://oncolifecentre.com/author/dr-christina-ng-van-tze/] 📍 Visit us at oncolifecentre.com [https://oncolifecentre.com] 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

19 de may de 20261 min